Keros Therapeutics appoints Christopher Rovaldi as COO effective Feb 1, 2022

Keros Therapeutics, Inc.

Christopher Rovaldi appointed Chief Operating Officer, effective February 1, 2022.
Rovaldi brings 20+ years experience, most recently as consultant and president of NS Biopharma Consulting.
Previously held senior roles at Acceleron Pharma (2007-2018), including SVP Program Management and Operations.
Initial annual base salary of $470,000; target bonus 50% of salary; option to purchase 100,000 shares.
Severance includes 9-12 months base salary and COBRA, with equity acceleration upon change of control termination.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher Rovaldi

Chief Operating Officer

KROS · Keros Therapeutics, Inc.

Effective: 2022-02-01
Filed: January 31, 2022, 6:59 PM ET

Christopher Rovaldi has been appointed to serve as the Company’s Chief Operating Officer, effective as of February 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Rovaldi was appointed as Chief Operating Officer at Keros Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Christopher Rovaldi has been appointed to serve as the Company’s Chief Operating Officer, effective as of February 1, 2022.

View on SEC.gov

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-22-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.